scispace - formally typeset
M

Michela Salvatici

Researcher at European Institute of Oncology

Publications -  39
Citations -  2101

Michela Salvatici is an academic researcher from European Institute of Oncology. The author has contributed to research in topics: Cardiotoxicity & Ejection fraction. The author has an hindex of 18, co-authored 38 publications receiving 1768 citations.

Papers
More filters
Journal ArticleDOI

N-Terminal Pro-B-Type Natriuretic Peptide after High-Dose Chemotherapy: A Marker Predictive of Cardiac Dysfunction?

TL;DR: Persistently increased NT-proBNP early after administration of HDC is strongly associated with development of cardiac dysfunction, and has important implications for identifying patients at risk of developing chemotherapy-induced cardiotoxicity.
Journal ArticleDOI

Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications

TL;DR: CTCs basal value is a predictive indicator of prognosis and changes in CTC levels during therapy may indicate a clinical response, which might substitute other measurement parameters for response evaluation.
Journal ArticleDOI

Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial

Daniela Cardinale, +136 more
TL;DR: Low cumulative doses of anthracyclines in adult patients with low cardiovascular risk can raise troponins, without differences between the two strategies of giving enalapril.
Journal ArticleDOI

Comparison of the Digene HC2 Assay and the Roche AMPLICOR Human Papillomavirus (HPV) Test for Detection of High-Risk HPV Genotypes in Cervical Samples

TL;DR: This study shows that the HC2 assay and the AMPLICOR HPV test give comparable results, with both being suitable for routine use, and the differences noted in some cases may suggest a different optimal clinical use.